A large retrospective real-world trial comprising more than 92,000 patients with respiratory allergies conducted in Denmark has established the effectiveness of allergy immunotherapy (AIT) in allergic rhinitis and asthma. The study, named REACT, was sponsored by ALK pharmaceuticals and included three major allergens – house dust mites, grass pollen and tree pollen. 

The trial found that patients with pre-existing asthma treated with AIT were more likely to step down their asthma treatment regimens, with a reduced likelihood of stepping up again. The ALK team has highlighted the importance of the long-term data provided by REACT and the effectiveness of ALT’s products in regulating serious asthma and rhinitis.